2025
Medications for Weight Loss and MASLD: A National Survey of Hepatology and Gastroenterology Provider Practices, Attitudes, and Knowledge Before Resmetirom.
Im G, Asgharpour A, Aby E, Stine J, Mellinger J, Luther J, Izzy M, Haque L, Lee B, Cotter T, Sherman C, Jophlin L, Goel A, Rice J, Chandna S, Lizaola-Mayo B, Chen P, Singal A, Bansal M. Medications for Weight Loss and MASLD: A National Survey of Hepatology and Gastroenterology Provider Practices, Attitudes, and Knowledge Before Resmetirom. Journal Of Clinical Gastroenterology 2025 PMID: 40549581, DOI: 10.1097/mcg.0000000000002147.Peer-Reviewed Original ResearchWeight loss medicationsGlucagon-like peptide-1Weight lossGastroenterology providersGlucagon-like peptide-1 receptor agonistsPrescribed off-label medicationsPrescribing weight loss medicationsOff-label medicationsFDA-approved medicationsLiver transplant centersOff-label prescribingMedication prescription ratesReceptor agonistsCost/insurance coveragePrescription ratesLiver diseaseSide effectsTransplant centersPeptide-1Steatotic liver diseaseObesity educationBenefit patientsPatientsResmetiromMedicationLetter: Response to Feder et al., Use of Hospice and End-of-Life Care Quality Among Medical Centers with High Versus Lower Specialist Palliative Care Reach Among People with Heart Failure: An Observational Study
Feder S, Shamas T, Akgün K. Letter: Response to Feder et al., Use of Hospice and End-of-Life Care Quality Among Medical Centers with High Versus Lower Specialist Palliative Care Reach Among People with Heart Failure: An Observational Study. Journal Of Palliative Medicine 2025 PMID: 40533098, DOI: 10.1089/jpm.2025.0317.Peer-Reviewed Original ResearchComparative Effectiveness of Long-Acting Injectable Vs. Oral Antipsychotic Medication After a First Episode of Psychosis: A Target Trial Emulation
Szmulewicz A, Martínez-Alés G, Ferrara M, Fredrikson D, Díaz-Caneja C, Sarpal D, Shinn A, Arango C, Öngür D, Hernán M. Comparative Effectiveness of Long-Acting Injectable Vs. Oral Antipsychotic Medication After a First Episode of Psychosis: A Target Trial Emulation. Biological Psychiatry 2025, 97: s52-s53. DOI: 10.1016/j.biopsych.2025.02.142.Peer-Reviewed Original ResearchSocio-ecologic Factors Impacting Medication Adherence Trajectories in Patients With Drug-resistant Tuberculosis and Human Immunodeficiency Virus
Guzman K, Wolf A, Perumal R, Cummings M, Zulu M, Zelnick J, Friedland G, Amico K, Reis K, Cheung Y, Daftary A, Seepamore B, Naidoo K, O'Donnell M. Socio-ecologic Factors Impacting Medication Adherence Trajectories in Patients With Drug-resistant Tuberculosis and Human Immunodeficiency Virus. American Journal Of Respiratory And Critical Care Medicine 2025, 211: a1036-a1036. DOI: 10.1164/ajrccm.2025.211.abstracts.a1036.Peer-Reviewed Original ResearchEmergency Medicine Resident Experiences and Perceptions Regarding Medications for the Treatment of Alcohol Use Disorder
Bia J, Hawk K. Emergency Medicine Resident Experiences and Perceptions Regarding Medications for the Treatment of Alcohol Use Disorder. Journal Of Emergency Medicine 2025 DOI: 10.1016/j.jemermed.2025.05.008.Peer-Reviewed Original ResearchAlcohol use disorderTreatment of alcohol use disordersPrescribed naltrexoneUse disorderEM residentsEmergency departmentEmergency medicineResident experienceEmergency medicine resident experiencesLack of timeLack of followReducing alcohol useED patientsPrescribed treatmentAlcohol useMedicationED visitsLack of teachingNaltrexoneNumerous barriersResidents' knowledgeLack of knowledgeTraining programTreatmentHealth consequences482. Associations Between Antipsychotic Medications and White Matter, Cognition, Ocular Motor Variables, and Psychosis Symptoms
Dumas E, Brown J, Tamminga C, Ivleva E, Hill S, Pearlson G, Gershon E, Keedy S, Keshavan M, Clementz B, McDowell J. 482. Associations Between Antipsychotic Medications and White Matter, Cognition, Ocular Motor Variables, and Psychosis Symptoms. Biological Psychiatry 2025, 97: s296. DOI: 10.1016/j.biopsych.2025.02.720.Peer-Reviewed Original ResearchImpact of an electronically‐integrated clinical pathway on hospital initiation of medications for alcohol use disorder and subsequent hospital utilization
Cole K, Weimer M, Wang K, Fiellin D, Advani A, Shah N, Zemaitis C, Rhodes D. Impact of an electronically‐integrated clinical pathway on hospital initiation of medications for alcohol use disorder and subsequent hospital utilization. Journal Of Hospital Medicine 2025 PMID: 40221929, DOI: 10.1002/jhm.70049.Peer-Reviewed Original ResearchClinical pathwayAlcohol use disorderED returnUse disorderHospital-based strategiesAcademic medical centerTertiary academic medical centerDays of dischargeHospital InitiativeInitiation of medicationHealth systemHospital utilizationMultiple barriersIncreased oddsConsecutive adult inpatientsHospital dischargeSecondary outcomesIncreased low ratesAdult inpatientsMedical CenterTreatment initiationHospitalVoluntary useReadmissionMedicationCorrection: Promoting alcohol treatment engagement post-hospitalization with brief intervention, medications and CBT4CBT: protocol for a randomized clinical trial in a diverse patient population
Edelman E, Rojas-Perez O, Nich C, Corvino J, Frankforter T, Gordon D, Jordan A, Paris, Jr M, Weimer M, Yates B, Williams E, Kiluk B. Correction: Promoting alcohol treatment engagement post-hospitalization with brief intervention, medications and CBT4CBT: protocol for a randomized clinical trial in a diverse patient population. Addiction Science & Clinical Practice 2025, 20: 29. PMID: 40128914, PMCID: PMC11931771, DOI: 10.1186/s13722-025-00558-x.Peer-Reviewed Original ResearchCivil Rights Laws for People With Opioid Use Disorder in the Emergency Department.
South A, Hawk K, Friedman S, Lofwall M, Fanucchi L, Cohen S. Civil Rights Laws for People With Opioid Use Disorder in the Emergency Department. Journal Of Addiction Medicine 2025 PMID: 40125857, DOI: 10.1097/adm.0000000000001480.Peer-Reviewed Original ResearchCivil rights lawsRights lawFederal civil rights lawOpioid use disorderLegal advocacyLegal liabilityUse disorderEmergency departmentAdoption of evidence-based practicesLawHealth care facilitiesHealth care systemEvidence-based practiceTreat opioid use disorderEvidence-based medicationsFatal overdoseRisk of deathOverdose crisisCare facilitiesCare systemEmergency cliniciansOutpatient treatmentEngage peopleLiabilityMedicationEffect of digital adherence technologies on treatment outcomes in people with drug-susceptible tuberculosis: four pragmatic, cluster-randomised trials
Jerene D, van Kalmthout K, Levy J, Alacapa J, Deyanova N, Dube T, Mganga A, Tasca B, Bogdanov A, Efo E, Gamazina K, Garfin A, Kochanov V, Leung A, Madden N, Maraba N, McQuaid C, Mleoh L, Onjare B, Powers R, Terleiva Y, van Rest J, Gebhard A, Fielding K, Charalambous S. Effect of digital adherence technologies on treatment outcomes in people with drug-susceptible tuberculosis: four pragmatic, cluster-randomised trials. The Lancet 2025, 405: 1155-1166. PMID: 40086457, DOI: 10.1016/s0140-6736(24)02847-2.Peer-Reviewed Original ResearchDrug-susceptible tuberculosisTreatment outcomesPoor treatment outcomesPrimary outcomeDigital adherence technologiesIntervention armCluster randomised trialIntention-to-treat populationStandard of care armTuberculosis treatment outcomesDocumented treatment failureLoss to follow-upStandard of careAdherence technologiesTreatment failureTreatment startAdult patientsFollow-upPatientsTreatment statusPatient outcomesCare armTuberculosisMedicationTrialsMedications for opioid use disorder in traditional medicare beneficiaries: associations with age
Ganz D, Lai J, Cantor J, Agniel D, Simon K, Stein B, Taylor E. Medications for opioid use disorder in traditional medicare beneficiaries: associations with age. Health Affairs Scholar 2025, 3: qxaf036. PMID: 40040649, PMCID: PMC11878533, DOI: 10.1093/haschl/qxaf036.Peer-Reviewed Original ResearchOpioid use disorderMOUD initiationIndex eventUse disorderTreat opioid use disorderAssociated with female sexRates of opioid use disorderIncreasing comorbidity scoreMultivariate logistic regressionAssociated with ageComorbidity scoreMedicare beneficiariesFemale sexOlder adultsAge-specific strategiesIncreased uptakeLogistic regressionOlder ageTraditional Medicare beneficiariesMOUDClaims dataMedicationPatient-reported strategies for prevention and treatment of chemotherapy-induced peripheral neuropathy
Hertz D, Tanay M, Tofthagen C, Rossi E, Bernasconi D, Sheffield K, Carlson M, Nekhlyudov L, Grech L, Von Ah D, Mayo S, Ruddy K, Chan A, Alberti P, Lustberg M. Patient-reported strategies for prevention and treatment of chemotherapy-induced peripheral neuropathy. Supportive Care In Cancer 2025, 33: 142. PMID: 39899120, DOI: 10.1007/s00520-025-09190-6.Peer-Reviewed Original ResearchConceptsSelf-reported peripheral neuropathyCross-sectional online surveyGuideline-recommended strategyEvidence of effectivenessNon-prescribed medicationTreating CIPNPurposeChemotherapy-induced peripheral neuropathyChemotherapy-induced peripheral neuropathyPeripheral neuropathyClinical teamStrategies patientsPrescription medicationsNeurotoxic chemotherapy treatmentMultinational AssociationDescriptive statisticsPrescribed medicationsSurvey participantsPrevention strategiesGuideline-recommendedTreatment of chemotherapy-induced peripheral neuropathyOnline surveyCIPNDebilitating toxicityImprove treatment outcomesMedicationPain Management in the Older Adults A Narrative Review
Rajput K, Ng J, Zwolinski N, Chow R. Pain Management in the Older Adults A Narrative Review. Clinics In Geriatric Medicine 2025, 41: 131-151. PMID: 39551538, DOI: 10.1016/j.cger.2024.03.011.Peer-Reviewed Original ResearchConceptsPain managementOlder adult populationOlder adult patientsOlder adultsAdult populationMultiple medicationsLife expectancyClinical practiceAdult patientsMedical managementPreexisting comorbiditiesPainUnited StatesDegenerative processPracticeNonagenariansMedicationAdultsComorbiditiesReviewManagementOctogenariansPatientsAficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy MAPLE-HCM Rationale, Study Design, and Baseline Characteristics
Garcia-Pavia P, Bilen O, Burroughs M, Costabel J, de Barros Correia E, Dybro A, Elliott P, Lakdawala N, Mann A, Nair A, Nassif M, Poulsen S, Reant P, Schulze P, Wang A, Berhane I, Heitner S, Jacoby D, Kupfer S, Malik F, Meng L, Sohn R, Wohltman A, Fifer M, Investigators M. Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy MAPLE-HCM Rationale, Study Design, and Baseline Characteristics. JACC Heart Failure 2025, 13: 346-357. PMID: 39909646, DOI: 10.1016/j.jchf.2024.11.011.Peer-Reviewed Original ResearchConceptsObstructive hypertrophic cardiomyopathyStandard-of-careCardiac myosin inhibitorStandard-of-care medicationsBaseline characteristicsSymptomatic obstructive hypertrophic cardiomyopathyNondihydropyridine calcium channel blockersBaseline characteristics of patientsStandard-of-care drugsSecond-line therapyFirst-line therapyCalcium channel blockersCharacteristics of patientsImprove exercise capacityMyosin inhibitorFirst-lineBeta-blockersHypertrophic cardiomyopathyExercise capacityAlleviate symptomsPatientsAficamtenMedicationTherapyStudy designWhat Is Science-Based Therapy?
Tolin D, Hupp S. What Is Science-Based Therapy? 2025, 1-10. DOI: 10.1017/9781009086264.002.Peer-Reviewed Original ResearchPostscript
Boness C, Hupp S, Tolin D. Postscript. 2025, 399-405. DOI: 10.1017/9781009086264.023.Peer-Reviewed Original ResearchPregnant Patient for Non-Obstetric Surgery
Salimi N, Fardelmann K. Pregnant Patient for Non-Obstetric Surgery. 2025, 345-357. DOI: 10.1093/med/9780190902001.003.0031.Peer-Reviewed Original ResearchNon-obstetric surgeryPregnant patientsFetal outcomesAdverse fetal outcomesFetal morbidityGestational ageNon-obstetricSurgeryNeurocognitive developmentOrthopedic proceduresAnesthetic exposurePatientsAnesthetic agentsMultidisciplinary approachPregnancyDelayed careOutcomesNeonatologyObstetricsMorbidityTeratogenicityAnesthesiaMedicationMortalityEthical principlesUtility and timeliness of a pharmaceutical mass casualty incident cart
Garcia-Dolagaray G, Doukas D, Silverberg M, Mcmahon J, Gutierrez F, Daniel P. Utility and timeliness of a pharmaceutical mass casualty incident cart. International Journal Of Academic Medicine 2025, 11: 22-25. DOI: 10.4103/ijam.ijam_118_24.Peer-Reviewed Original ResearchMass casualty incidentsEmergency departmentMass Casualty Incident drillsSystems-based practiceInner city hospitalInflux of patientsHazard vulnerability analysisMedication accessMedication cartMultidisciplinary teamPatientsCity HospitalCasualty incidentsMedicationBurn victimsCore competenciesPharmaceutical agentsPharmacyHospitalNotification systemPharmaceutical supplies
2024
Efficacy of antiobesity medications for weight reduction in older adults: a systematic review
Chen A, Hajduk A, Grimshaw A, Fried T, Jastreboff A, Lipska K. Efficacy of antiobesity medications for weight reduction in older adults: a systematic review. Obesity 2024 PMID: 39725567, PMCID: PMC12198421, DOI: 10.1002/oby.24160.Peer-Reviewed Original ResearchOlder adultsAntiobesity medicationsStudy of older adultsOlder adults ageAdult ageCardiovascular diseaseRisk of biasAdverse events associated with useWeight reductionStatistically significant weight reductionFood and Drug AdministrationClinical careSystematic reviewInclusion criteriaLimited evidenceBaseline weightPlacebo groupObservational studySeven medicationsAdverse eventsAdultsDrug AdministrationEvaluation studiesMedicationSignificant weight reductionHepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status
Re V, Newcomb C, Carbonari D, Mezochow A, Hennessy S, Rentsch C, Park L, Tate J, Bräu N, Bhattacharya D, Lim J, Mezzacappa C, Njei B, Roy J, Taddei T, Justice A, Torgersen J. Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status. Pharmacoepidemiology And Drug Safety 2024, 33: e70069. PMID: 39662972, PMCID: PMC11634562, DOI: 10.1002/pds.70069.Peer-Reviewed Original ResearchConceptsProton pump inhibitor initiationHazard ratioVeterans Health AdministrationSevere acute liver injuryProton pump inhibitorsChronic liver diseaseAcute liver injuryRates of hospitalizationSafety of medicationsPPI initiativesHealth AdministrationLiver disease statusMedication exposurePharmacoepidemiological studiesMedicationConfoundingScoresReports of hepatotoxicityDisease statusHepatotoxic medicationsDrug exposurePump inhibitorsHepatotoxic drugsOutpatient initiationHepatic safety
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply